Skip to main content

Free Content Insomnia symptoms and subsequent cardiovascular medication: a register‐linked follow‐up study among middle‐aged employees

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Sleep disturbances have been associated with an increased risk of cardiovascular disease outcomes. The associations of insomnia with hypertension and dyslipidaemia, the main modifiable cardiovascular risk factors, are less studied. We especially lack understanding on the longitudinal effects of insomnia on dyslipidaemia. We aimed to examine the associations of insomnia symptoms with subsequent prescribed medication for hypertension and dyslipidaemia using objective register‐based follow‐up data. Baseline questionnaire surveys among 40–60‐year‐old employees of the City of Helsinki, Finland, were conducted in 2000–2002 (= 6477, response rate 67%, 78% women) and linked to a national register on prescribed reimbursed medication 5–7 years prior to and 5 years after baseline. Associations between the frequency of insomnia symptoms (difficulties in initiating and maintaining sleep, non‐restorative sleep) and hypertension and dyslipidaemia medication during the follow‐up were analysed using logistic regression analysis (odds ratios with 95% confidence intervals). Analyses were adjusted for pre‐baseline medication, sociodemographic and work‐related factors, health behaviours, mental health, and diabetes. Frequent insomnia symptoms were reported by 20%. During the 5‐year follow‐up, 32% had hypertension medication and 15% dyslipidaemia medication. Adjusting for age, gender and pre‐baseline medication, frequent insomnia symptoms were associated with hypertension medication (odds ratio 1.57, 95% confidence interval 1.23–2.00) and dyslipidaemia medication (odds ratio 1.59, 95% confidence interval 1.19–2.12). Occasional insomnia symptoms were also associated with cardiovascular medication, though less strongly. Further adjustments had negligible effects. To conclude, insomnia should be taken into account in the prevention and management of cardiovascular disease and related risk factors.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: cardiovascular disease; dyslipidaemia; follow‐up study; hypertension; insomnia; register data

Document Type: Research Article

Publication date: 2014-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more